t(11;14) myeloma (~15-20%) — distinct biology with high BCL2/MCL1 ratio. Venetoclax monot...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-CCND1-T1114-MM |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-MM |
| Sources | SRC-ESMO-MM-2023 SRC-NCCN-MM-2025 |
Actionability Facts
| Biomarker | BIO-T11-14-IGH-CCND1 |
|---|---|
| Variant | t(11;14)(q13;q32) IGH/CCND1 |
| Disease | DIS-MM |
| ESCAT tier | IIA |
| Recommended combinations | venetoclax + dexamethasone (R/R t(11;14)-selected, off-label NCCN-supported), venetoclax + carfilzomib + dex (NCT trials) |
| Contraindicated monotherapy | venetoclax in non-t(11;14) MM (BELLINI mortality signal) |
| Evidence summary | t(11;14) myeloma (~15-20%) — distinct biology with high BCL2/MCL1 ratio. Venetoclax monotherapy (M14-032; Kumar Blood 2017 ORR ~40%) and venetoclax + dexamethasone (BELLINI subgroup; Kumar Lancet Oncol 2020) active. BELLINI raised mortality signal in non-t(11;14) arm — venetoclax is now t(11;14)-selected in MM. CANOVA Ph3 (venetoclax + dex vs pomalidomide + dex in t(11;14) R/R MM) read out 2024. |
Notes
ESCAT IIA. OncoKB Level 3A. FISH t(11;14) reflex testing should be standard at MM workup. NCCN listed as preferred R/R option in t(11;14)+ patients.
Used By
No reverse references found in the YAML corpus.